AAIC 2025 Abstract
Blood biomarkers for Alzheimer's disease are correlated with treatment outcomes in a randomized trial assessing the effects of escitalopram on agitation
Trial in peopleBiomarkers
Abstract
Background: Escitalopram for Agitation in Alzheimer's Disease (S‐CitAD) was an NIH‐funded RCT that randomized 173 participants with Alzheimer's Disease (AD) and agitation to escitalopram or placebo for 12 weeks assessing efficacy for clinically significant agitation.
